Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded by RODMAN&RENSHAW to “Strong-Buy” Rating

RODMAN&RENSHAW upgraded shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) to a strong-buy rating in a research note issued to investors on Thursday morning,Zacks.com reports.

Separately, Rodman & Renshaw started coverage on Eupraxia Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $9.00 target price on the stock.

Eupraxia Pharmaceuticals Trading Up 7.9 %

Shares of NASDAQ:EPRX opened at $3.13 on Thursday. Eupraxia Pharmaceuticals has a 12 month low of $2.20 and a 12 month high of $5.58. The company has a market capitalization of $85.39 million and a price-to-earnings ratio of -4.35. The firm’s 50-day moving average is $2.67 and its 200 day moving average is $2.68.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

A hedge fund recently bought a new stake in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC bought a new stake in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 13,000 shares of the company’s stock, valued at approximately $34,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.